{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:18:21Z","timestamp":1769231901915,"version":"3.49.0"},"reference-count":28,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,3,14]]},"abstract":"<jats:p>A 60-year-old woman with major depressive disorder, developed high blood pressure, confusion and dyskinesias of face, neck and jaw, following an increase in her dose of duloxetine. Routine blood tests including toxic, infective and metabolic workup were unremarkable. Cerebrospinal fluid analysis and electroencephalogram were also normal. MRI brain showed bilaterally symmetrical diffusion-restricted areas in deep cerebral white matter. Duloxetine was held on suspicion of drug adverse effect. She had complete resolution of symptoms within 48\u2009hours and resolution of MRI brain changes over 6 weeks. Serotonin norepinephrine reuptake inhibitors such as duloxetine may have the potential to cause drug-induced movement disorders, confusion and high blood pressure and should be used cautiously especially in elderly.<\/jats:p>","DOI":"10.1136\/bcr-2016-216746","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T13:50:28Z","timestamp":1522245028000},"page":"bcr-2016-216746","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Drug-induced movement disorder and confusion associated with duloxetine"],"prefix":"10.1136","volume":"2018","author":[{"given":"Sarah Hasan","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem Ahmed","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Shanker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.1","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.12.002"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.06.031"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.08.041"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.5","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003747441"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2012.00578.x"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.7","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050006"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-951608"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.9","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2013.10.1.95"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.10","unstructured":"US Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin\u2013norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm085845.htm (accessed 23 Jul 2016)."},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(99)03514-X","article-title":"Neuroleptic malignant syndrome after venlafaxine","volume":"355","author":"Nimmagadda","year":"2000","journal-title":"The Lancet"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.12","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/459321"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2006.100222"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2165\/00002018-199716030-00004","article-title":"Drug-induced movement disorders","volume":"16","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1997","journal-title":"Drug Saf"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.15","doi-asserted-by":"publisher","DOI":"10.1177\/0897190007310514"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.16","first-page":"148","article-title":"Extrapyramidal symptoms associated with antidepressants \u2013 a review of the literature and an analysis of spontaneous reports","volume":"22","author":"Madhusoodanan","year":"2010","journal-title":"Ann Clin Psychiatry"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2008.10.001"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.03.015"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.19","doi-asserted-by":"crossref","first-page":"646.e9","DOI":"10.1016\/j.genhosppsych.2010.04.009","article-title":"Duloxetine-related tardive dystonia and tardive dyskinesia: a case report","volume":"32","author":"Chen","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.20","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182686619"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.21","doi-asserted-by":"crossref","unstructured":"Friedman JH . Medication-induced movement disorders. Cambridge University Press, 2015. Cambridge Books Online. http:\/\/dx.doi.org\/10.1017\/CBO9781107588738 (accessed on 23 Jul 2016).","DOI":"10.1017\/CBO9781107588738.001"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.22","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.5.587"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.23","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg109"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/JCP.0b013e31823fb238","article-title":"Treatment with duloxetine in adults and the incidence of cardiovascular events","volume":"32","author":"Xue","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DDDT.S4358","article-title":"Continuation treatment of major depressive disorder: is there a case for duloxetine?","volume":"4","author":"Norman","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.26","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.162.3.8109519"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.27","first-page":"24","article-title":"Reversible posterior leucoencephalopathy syndrome following duloxetine: a case report and review of literature","volume":"2","author":"Chhakchhuak","year":"2011","journal-title":"J Med Cases"},{"key":"2025042703144819000_2018.mar28_1.bcr-2016-216746.28","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2024"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-216746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:15:01Z","timestamp":1745748901000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-216746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":28,"alternative-id":["10.1136\/bcr-2016-216746"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-216746","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]}}}